EHA Unplugged

00:14:55

How to Improve Equity and Inclusion in Hematology:...

EHA Unplugged ·

2026/10/02

In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies. The discussion explores the

en

00:20:41

Advancing Adult ALL Care in Europe: EHA2026 Clinical...

EHA Unplugged ·

2026/09/25

In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are

en

00:22:45

Refining Transplantation and Cellular Therapy:...

EHA Unplugged ·

2026/09/22

In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across

en

00:21:31

What Can We Learn About AML from Clonal...

EHA Unplugged ·

2026/09/18

In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. The discussion also explores efforts to

en

00:21:10

Improving MPNs management: EHA2026 Lifetime...

EHA Unplugged ·

2026/09/15

In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. The discussion explores landmark studies that helped

en

00:17:44

CAR T Toxicities in Focus: What We Have Learned from...

EHA Unplugged ·

2026/09/09

In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune

en

00:21:05

Life After YERM: How the Young EHA Research Meeting...

EHA Unplugged ·

2026/09/06

In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers.Guests: Dr Mattias

en

00:19:28

Discover YERM: The Young EHA Research Meeting and...

EHA Unplugged ·

2026/09/06

Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM. Guests:  Prof Ruud Delwel, Erasmus Medical Centre, The NetherlandsProf Marlies Vanden Bempt, KU

en

00:21:34

CAR-T for Pediatric B-ALL: Expert Tips

EHA Unplugged ·

2026/08/28

In this episode, Prof André Baruchel discusses the role of CAR T-cell therapy in children with B-cell acute lymphoblastic leukemia (B-ALL). He reviews current indications for CAR T-cell treatment, including relapsed and refractory disease, and explores whether CAR T could move earlier in the treatment pathway. The discussion also examines how CAR T-cell therapy compares with transplantation, blinatumomab, and other salvage strategies, as well as the factors that influence long-term outcomes and

en

00:21:12

Getting Patients to CAR T: Referral Systems in Europe

EHA Unplugged ·

2026/08/25

In this episode of EHA Unplugged, Prof Marion Subklewe discusses one major challenge facing CAR T-cell therapy in Europe: ensuring that eligible patients are referred for treatment. She explains how access has improved since the first CAR T-cell approvals, but highlights that many eligible patients still do not receive these potentially curative therapies. The discussion explores differences between European healthcare systems, barriers to referral, and persistent misconceptions about patient

en

00:27:03

Outpatient CAR T in Europe: Lessons from Barcelona

EHA Unplugged ·

2026/08/21

In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantation and supportive care to outpatient CAR T administration, and describe the key clinical and logistical requirements for patient selection. The discussion explores caregiver training, monitoring for cytokine release syndrome

en

00:17:42

Smarter CARs: Using AI to Improve Chimeric Antigen...

EHA Unplugged ·

2026/08/18

Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, particularly at the design stage of the CAR receptor binding domains. Dr Schmidts explains how structure-based AI models can generate entirely new protein binders, moving beyond the traditional reliance on monoclonal

en

00:18:39

What is Real-World Evidence Revealing About CAR T...

EHA Unplugged ·

2026/08/17

In this episode, Prof Benoit Tessoulin examines how real-world evidence from the French DESCAR-T registry is expanding our understanding of CAR T-cell therapy beyond clinical trials. He explains how the registry captures data from patients considered for CAR T-cell treatment, including those who do not ultimately receive therapy, and explores what these data reveal about patient selection, treatment outcomes, bridging therapy, and comparisons between different CAR T-cell products. The discussion

en

00:22:40

Hematology Portraits: Prof Frank Leebeek

EHA Unplugged ·

2026/07/31

In this episode Prof. Frank Leebeek reflects on his career in hematology, highlighting a lifelong commitment to bridging clinical practice and research. From his early interest in fibrinolysis during medical school to his current role as Chair of the Department of Hematology at Erasmus Medical Center and Board member at EHA, Prof. Leebeek shares how a dual commitment to research and patient care has shaped his path. The conversation explores key milestones in bleeding disorders research, including

en

00:18:46

How to Start a Clinical Trial?

EHA Unplugged ·

2026/07/16

What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRTH) program helped shape his path. Prof. Mai reflects on the practical and often underappreciated challenges of clinical trial design—from budgeting and statistical planning to ethical considerations and regulatory

en

00:35:39

How Experts Treat Multiple Myeloma

EHA Unplugged ·

2026/07/03

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent therapeutic advances—including 14 newly approved treatment regimens, CAR T-cell therapies, bispecific antibodies and antibody-drug conjugates—have reshaped the treatment landscape and informed the latest recommendations. The

en

00:22:33

Where Are We Now With Immunotherapy in Multiple Myeloma?

EHA Unplugged ·

2026/06/22

Explore the latest advancements in immunotherapies for multiple myeloma, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. In this episode, Dr. Paula Rodriguez Otero discusses the strategic sequencing of BCMA and explains why CAR-T cells should often precede bispecific antibodies to maximize efficacy while managing toxicity. The episode highlights the potential for these therapies to replace transplants by inducing deep, durable responses. Dr. Otero also explores

en

00:19:42

Menin Inhibitors to Treat Acute Myeloid Leukemia (AML)

EHA Unplugged ·

2026/06/01

Get up to date on menin inhibitors, an emerging class of targeted therapies for acute myeloid leukemia (AML). Menin is a key component of the KMT2A (lysine methyltransferase 2A, formerly MLL1) complex, which plays a critical role in gene regulation, development, and cell cycle control. Small-molecule menin inhibitors have shown particular promise in KMT2A-rearranged (KMT2Ar) and NPM1-mutated AML, with two agents already receiving FDA breakthrough therapy designation. In this episode, Dr Scott

en

00:11:20

How Experts Treat HIV-associated Lymphomas

EHA Unplugged ·

2026/05/13

Get up to date with the EHA–ESMO guidelines on Human immunodeficiency virus (HIV)-associated Lymphomas. In this episode, Prof. Kai Hubel, a key author of the guidelines, explains the importance of having dedicated recommendations for patients with HIV-associated lymphomas. He begins by discussing the prevalence of lymphomas in people living with HIV, then highlights that the modern CART HIV treatment should be combined with the lymphoma treatments. This

en

00:18:30

Hematology Portraits: Associate Prof Meritxell...

EHA Unplugged ·

2026/05/07

Join Meritxell Alberich Jordà, an EHA Board member and a principal investigator from Prague, as she shares her journey to becoming a recognised research scientist in hematology, and the role EHA has played along the way. Her lab studies hematopoietic and leukemic stem cells, focusing on how disruptions in transcriptional regulation and inflammatory signalling drive the development and persistence of acute myeloid leukemia. Meri reflects on how her early research interests evolved over time, how key

en

All Episodes

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media